Group 1 - Citi has lowered the target price for Smoore International to HKD 21, maintaining an "Outperform" rating [1] - UBS has also reduced the target price for Smoore International to HKD 13.11, while maintaining a "Sell" rating [1]

Core Viewpoint - Citi has released a report predicting that Smoore International (06969) will experience a 44% year-on-year decline in net profit and a 7% decline in adjusted net profit for this year, with a recovery expected between 2026 and 2027 [1] Financial Performance - The company reported an 18% year-on-year increase in sales for the first half of the year, while net profit fell by 28% and adjusted net profit decreased by 2%, aligning with earlier profit warnings [1] - The decline in net profit is primarily attributed to a significant drop in sales in China and a decrease in gross margin due to product mix adjustments [1] Future Projections - The firm anticipates a gross margin of 36.4% for this year, improving to 38.8% next year [1] - From 2025 to 2027, the company is expected to achieve a compound annual growth rate (CAGR) of 16% in sales and 48% in adjusted net profit [1] Market Dynamics - Sales this year are expected to be driven mainly by capsule products, following the EU's ban on single-use e-cigarettes and the expansion of advanced personal vaporizers (APV) and heated non-combustible (HNB) products [1] Investment Strategy - The management indicated that this year will be an investment year, with an additional investment of 300 million RMB planned for research and development in medical and heated non-combustible products [1]

Core Viewpoint - Citi has lowered the target price for Smoore International (06969) to HKD 21, maintaining an "outperform" rating, anticipating a 44% decline in net profit and a 7% drop in adjusted net profit for this year, with recovery expected in 2026-2027 [1] Financial Performance - The company reported an 18% year-on-year increase in sales for the first half of the year, while net profit fell by 28% and adjusted net profit decreased by 2%, aligning with earlier profit warnings [1] - The expected gross margin for this year is 36.4%, with an increase to 38.8% projected for next year [1] Future Projections - The firm anticipates a compound annual growth rate (CAGR) of 16% in sales and 48% in adjusted net profit from 2025 to 2027 [1] - Sales in the current year are expected to be primarily driven by capsule products, following the EU's ban on single-use e-cigarettes and the expansion of advanced personal vaporizers (APV) and heated non-combustible (HNB) products [1] Investment Strategy - Management has indicated that this year will be an investment year, with an additional RMB 300 million allocated for research and development in medical and heated non-combustible products [1]

Core Points - The Singapore government announced stricter penalties for e-cigarette violations starting September 1, particularly targeting the use and sale of e-cigarettes containing banned substances [1] - The new regulations classify "etomidate" as a Class C drug under the Misuse of Drugs Act, with a temporary enforcement period of six months [1] - Individuals caught possessing, using, or purchasing e-cigarettes with harmful substances will face increased fines and mandatory rehabilitation programs, with repeat offenders facing harsher penalties [1] Regulatory Changes - Starting September 1, penalties for holding, using, or purchasing e-cigarettes will be increased, with first-time offenders facing higher fines and repeat offenders required to undergo a three-month rehabilitation program or face more severe penalties [1] - The maximum punishment for importing, selling, or distributing e-cigarettes containing etomidate includes up to 15 strokes of the cane and a maximum of 20 years in prison [1] Health Concerns - Etomidate is a sedative drug typically used for intravenous anesthesia, and its consumption through e-cigarettes can lead to severe side effects such as nausea, vomiting, seizures, and in severe cases, organ failure or death [2]

Group 1 - The core viewpoint is that Smoore International (06969) has experienced a significant decline in net profit for the first half of the year, primarily due to increased R&D expenses and other costs, leading to a drop in stock price [1][2] - For the first half of the year, Smoore International reported revenue of 6.013 billion RMB, an increase of 18.3% year-on-year, while adjusted net profit was 737 million RMB, a decrease of 2.1%, and net profit was 492 million RMB, down 27.96% [1] - The company declared an interim dividend of 0.20 HKD per share, compared to 0.05 HKD per share in the same period last year [1] Group 2 - UBS reported that the decline in net profit was largely due to increased stock-based compensation, rising sales and development expenses, and a higher tax rate [2] - Management remains optimistic about revenue growth in the second half of the year, citing favorable policies for e-cigarettes in the US and Europe, although short-term profitability will still be impacted by R&D expenses [2] - UBS has lowered its earnings forecast for the company from 10% to 33% for the years 2023 to 2027, reflecting higher sales, marketing, and R&D expenditures, and has reduced the target price from 14 HKD to 13.11 HKD while maintaining a "sell" rating [2]

Core Viewpoint - Smoore International (06969) experienced a significant decline in stock price following its interim results, with a drop of over 6% in early trading and a current price of 19.23 HKD, despite a revenue increase of 18.3% year-on-year [1] Financial Performance - The company reported a revenue of 6.013 billion RMB for the first half of the year, reflecting an 18.3% increase year-on-year [1] - Adjusted net profit for the period was 737 million RMB, a decrease of 2.1% year-on-year [1] - The overall profit for the period was 492 million RMB, down 27.96% year-on-year [1] - The interim dividend declared was 0.20 HKD per share, compared to 0.05 HKD per share in the same period last year [1] Analyst Insights - Bank of America noted that Smoore's performance was generally in line with expectations, predicting a slight improvement in annual revenue growth, but continued pressure on profit margins [1] - UBS reported that the decline in net profit was primarily due to increased stock-based compensation, higher sales and development expenses, and a rising tax rate [1] - Management expressed optimism for continued revenue growth in the second half, supported by favorable policies for e-cigarettes in the US and Europe, although short-term profitability will be impacted by increased R&D spending [1] - The company is preparing to launch its own products in the US, with specific financial results from new business segments expected to be reflected by 2027 [1] - UBS downgraded its earnings forecast for the company from 10% to 33% for the years 2023 to 2027, citing higher sales, marketing, and R&D expenses, and lowered the target price from 14 HKD to 13.11 HKD, maintaining a "sell" rating [1]

Group 1 - The stock price of Yinghe Technology closed at 23.01 yuan on August 26, 2025, down 1.46% from the previous trading day, with a trading volume of 689 million yuan and a turnover rate of 4.67% [1] - Yinghe Technology's main business includes lithium battery equipment manufacturing and e-cigarette operations, positioning it as a core equipment supplier in the new energy industry chain [1] - The company's products are widely used in power batteries and energy storage, with clients including leading companies such as CATL and BYD [1] Group 2 - According to the company's 2025 semi-annual report, the contract liabilities for lithium battery equipment business reached 2.525 billion yuan, an increase of 52.72% compared to the beginning of the year, indicating a strong order reserve [1] - The company has achieved technological breakthroughs in solid-state battery equipment, with related equipment already delivered for customer pilot line use [1] - In the e-cigarette business, the subsidiary Skoll is continuously expanding into overseas markets, focusing on Europe and North America [1] Group 3 - On August 26, the net outflow of main funds was 33.7564 million yuan, with a cumulative net outflow of 227 million yuan over the past five days [1]

Core Viewpoint - UBS has downgraded the target price for Smoore International (06969) to HKD 13.11 and maintained a "Sell" rating due to a decline in mid-term net profit primarily driven by increased equity compensation, rising sales and development expenses, and a higher tax rate [1] Financial Performance - Smoore International's mid-term net profit has decreased, largely attributed to increased equity compensation and higher sales and development expenditures [1] - The company's management remains optimistic about revenue growth in the second half of the year, citing favorable policies for e-cigarettes in the US and Europe [1] Future Outlook - Short-term profitability is expected to be impacted by increased R&D spending as the company prepares to launch its own products in the US [1] - More specific financial results from new business segments such as heated tobacco, inhalation therapy, and beauty aerosol products are anticipated to be reflected by 2027 [1] Earnings Forecast - UBS has revised its earnings forecast for Smoore International for the years 2023 to 2027 down by 10% to 33%, reflecting higher sales, marketing, and R&D expenses [1]

Core Viewpoint - UBS report indicates that Smoore International's mid-term net profit has declined primarily due to increased equity compensation, rising sales and development expenses, and higher tax rates [1] Financial Performance - The management is optimistic about continued revenue growth in the second half of the year, supported by favorable e-cigarette policies in the US and Europe [1] - The company’s short-term profitability is still impacted by increased R&D expenses as it prepares to launch its own products in the US [1] Future Outlook - Management expects more specific financial results from new business segments such as heated tobacco, inhalation therapy, and beauty aerosol products to be reflected by 2027 [1] - UBS has lowered its earnings forecast for the company from this year to 2027 by 10% to 33%, reflecting higher sales, marketing, and R&D expenses [1] Target Price and Rating - The target price has been reduced from HKD 14 to HKD 13.11, while maintaining a "Sell" rating [1]

Core Viewpoint - UBS report indicates that Smoore International (06969) experienced a decline in mid-term net profit primarily due to increased equity compensation, rising sales and development expenses, and higher tax rates [1] Financial Performance - The management remains optimistic about revenue growth in the second half of the year, supported by favorable e-cigarette policies in the US and Europe [1] - The company’s short-term profitability is still impacted by higher R&D expenditures as it prepares to launch its own products in the US [1] Future Outlook - More specific financial results from new business segments such as heated tobacco, inhalation therapies, and beauty aerosol products are expected to be reflected by 2027 [1] - UBS has revised its earnings forecast for the company downwards by 10% to 33% for the years 2023 to 2027, reflecting increased sales, marketing, and R&D expenses [1] Target Price Adjustment - The target price for Smoore International has been reduced from HKD 14 to HKD 13.11, while maintaining a "Sell" rating [1]